ARTICLE | Emerging Company Profile
Exploiting alpha-GAL
How Agalimmune’s alpha-GAL can get endogenous antibodies to destroy solid tumors
November 4, 2016 6:44 PM UTC
By coating tumor cells with a synthetic carbohydrate, Agalimmune Ltd. can enlist naturally circulating polyclonal antibodies to destroy primary solid tumor cells and stimulate an adaptive immune response against metastases.
The newco’s Alphaject therapies are small molecule analogs of glycolipids expressing the galactose-alpha-1,3-galactosyl-beta-1,4-N-acetyl-glucosamine (alpha-GAL) epitope. ...
BCIQ Company Profiles
BCIQ Target Profiles
Galactose-alpha-1,3-galactosyl-beta-1,4-N-acetyl-glucosamine (alpha-GAL)